Promoter of TFPI-2 is Hypermethylated in Chinese Pediatric Acute Myeloid Leukemia

Pan Jian,Wu Shui Yan,Sun Li Chao,Peng Liang,Li Zhen,Qiu Bao Ling,Li Yan Hong,Li Yi Ping,Wang Jian,Jing Mei Fang,Liu Ling,Wang Xing Dong,Zhu Xue Ming,Ni Jian
DOI: https://doi.org/10.1097/mph.0b013e3182277276
2012-01-01
Journal of Pediatric Hematology/Oncology
Abstract:Human tissue factor pathway inhibitor-2 (TFPI-2) has been implicated as a metastasis-associated gene in many types of tumors. In this study, we investigated whether TFPI-2 was inactivated epigenetically in pediatric acute myeloid leukemia (AML). Methylation status was investigated by methylation-specific polymerase chain reaction and bisulfate genomic sequencing. TFPI-2 was aberrantly methylated in 50% (3/6) of AML cell lines. Aberrant methylation of TFPI-2 promoter was detected in 71.6% (48/67) of the Chinese pediatric AML patients. TFPI-2 transcript was significantly lower in AML group compared with controls (3.44 vs. 32.8, P<0.001). Patients with methylated TFPI-2 gene had significantly lower TFPI-2 transcript than those patients without methylated TFPI-2 (P=0.04). Promoter hypermethylation of TFPI-2 is frequent and specific event in pediatric AML.
What problem does this paper attempt to address?